Skip to main content
SpringerLink
Log in

Mechanisms for Cisplatin-FUra Synergism and Cisplatin Resistance in Human Ovarian Carcinoma Cells both in vitro and in vivo

  • Chapter
  • First Online:
Book cover The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 244))

Abstract

Cisplatin and FUra act synergisticly in human carcinomas. An increase in the availability of reduced folates necessary for tight binding of FdUMP to thymidylate synthase (TS) contributes to the enhanced cytotoxicity of this drug combination. The human ovarian A2780 cell line made three-fold resistant to cisplatin has been shown to have a three-fold elevation of m-RNA for dihydrofolate reductase (DHFR) and TS. However, this increase did not result from an amplification of the genes for these two enzymes. In contrast, ovarian carcinoma cells from patients who failed treatment with cisplatin and FUra have been shown to have both enhanced gene expression and increased gene copy number for DHFR and TS.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. B. Rosenberg, Fundamental studies with cisplatin, Cancer. 55: 2303 (1985).

    Article  CAS  Google Scholar 

  2. R. F. Ozols and R. C. Young, Chemotherapy of ovarian cancer, Sem. in Oncol. 11:257 (1984).

    Google Scholar 

  3. F. M. Schabel, H. E. Skipper, M. W. Trader, W. R. Laster, D. P. Griswold, and T. H. Corbett, Establishment of cross-resistance profiles for new agents, Cancer Treat. Rea. 67: 905 (1983).

    Google Scholar 

  4. A. Rosowsky, J. E. Wright, C. A. Cucchi, J. L. Flatow, D. H. Trites, B. A. Teicher, and E. Frei, Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II), Cancer Res. 47: 5913 (1987).

    CAS  PubMed  Google Scholar 

  5. E. M. Newman, Y. Lu, M. Kashani-Sabet, V. Kesavan, and K. J. Scanlon, Biochemical basis for cisplatinum resistance in human ovarian carcinoma cells, Biochem. Pharm. 37: 443 (1988).

    Article  CAS  Google Scholar 

  6. Y. Lu, J. Han, and K. J. Scanlon, Biochemical and molecular properties of cisplatin resistance in A2780 cells grown in folinic acid, J. Biol. Chem. 263: 4891 (1988).

    CAS  PubMed  Google Scholar 

  7. K. J. Scanlon, M. Kashani-Sabet, A. R. Cashmore, M. Pallai, B. A. Moroson, and M. Saketos, The role of methionine in methotrexate sensitive and resistant mouse leukemia L1210 cells, Cancer Chemother. Pharm. 19: 25 (1987).

    Article  CAS  Google Scholar 

  8. K. J. Scanlon, R. Safirstein, H. Thies, R. B. Gross, S. Waxman, and J. B. Guttenplan, Inhibition of amino acid transport by cisplatin and its derivatives in L1210 murine leukemia cells, Cancer Res. 43: 4211 (1983).

    CAS  Google Scholar 

  9. K. J. Scanlon, E. M. Newman, Y. Lu, and D. G. Priest, Biochemical basis for cisplatinum and 5-fluorouracil synergism in human ovarian carcinoma cells, Proc. Natl. Acad. Sci. USA 83: 8923 (1986).

    Article  CAS  Google Scholar 

  10. K. J. Scanlon and M. Kashani-Sabet, Elevated expression of dTMP synthase cycle genes in cisplatin-resistant A2780 cells, Proc. Natl. Acad. Sci. USA 85: 650 (1988).

    Article  CAS  Google Scholar 

  11. J. Chen and K. J. Scanlon, Molecular and biochemical properties of cisplatin-resistant HCT8 human colon carcinoma cells, Amer. Assoc. Cancer Res. 29: 1431 (1988).

    Google Scholar 

  12. A. Eva, K. C. Robbins, P. R. Andersen, A. Srinivasan, S. R. Tronick, E. P. Reddy, N. W. Ellmore, A. T. Galen, J. A. Lantenberger, T. S. Papas, E. H. Westin, F. Wong-Stall, R. C. Gallo, and S. A. Aaronson, Cellular genes analogous to retroviral one genes are transcribed in human tumour cells, Nature, Lond. 295: 116 (1982).

    Article  CAS  Google Scholar 

  13. B. J. Rollins, and C. D. Stiles, Regulation of c-myc and c-fos proto-oncogene expression by animal cell growth factors, In Vitro Cellular and Developmental Biol. 24: 81 (1988).

    Article  CAS  Google Scholar 

  14. M. Kashani-Sabet, J. J. Rossi, Y. Lu, J. Chen, H. Miyachi, J. x. Ma, D.Blaney, L. Leong, and K. J. Scanlon, Early detection of cisplatin resistance in fresh human carcinoma cells by in vitro enzymatic amplification assay, Amer. Assoc. Cancer Res. 29: 1159 (1988).

    Google Scholar 

  15. M. D. Sklar, Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3TE cells transformed by ras oncogenes, Cancer Res. 48: 793 (1988).

    CAS  PubMed  Google Scholar 

  16. L. Vanhamme and C. Szpirer, Methionine metabolism defect in cells transfected with an activated HRAS1 oncogene, Exp. Cell Res. 169: 120 (1987).

    Article  CAS  Google Scholar 

  17. R. B. Gross and K. J. Scanlon, Membrane transport properties of L1210 cells resistant to cisplatin, Chemoterapia 5: 37 (1986).

    CAS  Google Scholar 

  18. S. Shionoya, Y. Lu, and K. J. Scanlon, Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II), Cancer Res. 46: 3445 (1986).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Biochemical Pharmacology, Medical Oncology, Duarte, CA, 91010, USA

    K. J. Scanlon, Y. Lu, M. Kashani-Sabet & J. x. Ma

  2. Division of Pediatrics, City of Hope National Medical Center, Duarte, CA, 91010, USA

    E. Newman

Authors
  1. K. J. Scanlon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Kashani-Sabet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. x. Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Newman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Roswell Park Memorial Institute, Buffalo, New York, USA

    Youcef Rustum  & John J. McGuire  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Plenum Press, New York

About this chapter

Cite this chapter

Scanlon, K.J., Lu, Y., Kashani-Sabet, M., x. Ma, J., Newman, E. (1988). Mechanisms for Cisplatin-FUra Synergism and Cisplatin Resistance in Human Ovarian Carcinoma Cells both in vitro and in vivo . In: Rustum, Y., McGuire, J.J. (eds) The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy. Advances in Experimental Medicine and Biology, vol 244. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-5607-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-5607-3_12

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4684-5609-7

  • Online ISBN: 978-1-4684-5607-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation